The comparative metabonomics of age-related changes in the urinary composition of male Wistar-derived and Zucker (fa/fa) obese rats.

The global metabolite profiles of endogenous compounds excreted in urine by male Wistar-derived and Zucker (fa/fa) obese rats were investigated from 4 to 20 weeks of age using both 1H NMR spectroscopy and HPLC-TOF/MS with electrospray ionisation (ESI). Multivariate data analysis was then performed on the resulting data which showed that the composition of the samples changed with age, enabling age-related metabolic trajectories to be constructed. At 4 weeks it was possible to observe differences between the urinary metabolite profiles from the two strains, with the difference becoming more pronounced over time resulting in a marked divergence in their metabolic trajectories at 8-10 weeks. The changes in metabolite profiles detected using 1H NMR spectroscopy included increased protein and glucose combined with reduced taurine concentrations in the urine of the Zucker animals compared to the Wistar-derived strain. In the case of HPLC-MS a number of ions were found to be present at increased levels in the urine of 20 week old Zucker rats compared to Wistar-derived rats including m/z 71.0204, 111.0054, 115.0019, 133.0167 and 149.0454 (negative ion ESI) and m/z 97.0764 and 162.1147 (positive ion ESI). Conversely, ions m/z 101.026 and 173.085 (negative ion ESI) and m/z 187.144 and 215.103 (positive ion ESI) were present in decreased amounts in urine from Zucker compared to Wistar-derived rats. Metabolite identities proposed for these ions include fumarate, maleate, furoic acid, ribose, suberic acid, carnitine and pyrimidine nucleoside. The utility of applying metabonomics to understanding disease processes and the biological relevance of some of the findings are discussed.

[1]  E Holmes,et al.  Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. , 1998, Chemical research in toxicology.

[2]  Jinhai Gao,et al.  Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors , 2004, Nature.

[3]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[4]  E Holmes,et al.  NMR spectroscopy based metabonomic studies on the comparative biochemistry of the kidney and urine of the bank vole (Clethrionomys glareolus), wood mouse (Apodemus sylvaticus), white toothed shrew (Crocidura suaveolens) and the laboratory rat. , 2000, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[5]  I. Wilson,et al.  Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. , 2004, Journal of pharmaceutical and biomedical analysis.

[6]  I. Wilson,et al.  Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLS‐DA , 2002, FEBS letters.

[7]  S. Kagamimori,et al.  Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects , 2004, Amino Acids.

[8]  M. Reily,et al.  Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[9]  I. Wilson,et al.  A combined (1)H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. , 2005, Journal of pharmaceutical and biomedical analysis.

[10]  Ina Schuppe-Koistinen,et al.  Screening of biomarkers in rat urine using LC/electrospray ionization-MS and two-way data analysis. , 2003, Analytical chemistry.

[11]  Kai Huang,et al.  Taurine May Prevent Diabetic Rats from Developing Cardiomyopathy also by Downregulating Angiotensin II Type2 Receptor Expression , 2005, Cardiovascular Drugs and Therapy.

[12]  J. Jordan,et al.  Identification of an urinary metabolite profile associated with osteoarthritis. , 2005, Osteoarthritis and cartilage.

[13]  C. Waterfield,et al.  The in vivo and in vitro protective properties of taurine. , 1995, General pharmacology.

[14]  E. Lock,et al.  1H-Nuclear magnetic resonance pattern recognition studies with N-phenylanthranilic acid in the rat: time- and dose-related metabolic effects , 2003, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[15]  J. Nicholson,et al.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.

[16]  E Holmes,et al.  Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. , 2001, Chemical research in toxicology.

[17]  E. Lock,et al.  1H NMR pattern recognition and 31P NMR studies with d-Serine in rat urine and kidney, time- and dose-related metabolic effects. , 2003, Chemical research in toxicology.

[18]  J. Lindon,et al.  'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  Guowang Xu,et al.  Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  M. Rantalainen,et al.  The metabonomics of aging and development in the rat: an investigation into the effect of age on the profile of endogenous metabolites in the urine of male rats using 1H NMR and HPLC-TOF MS. , 2005, Molecular bioSystems.

[21]  J. Maturo,et al.  Hypoglycemic properties of taurine: not mediated by enhanced insulin release. , 1984, Biochemical pharmacology.

[22]  I. Wilson,et al.  An NMR‐based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse , 2000, FEBS letters.

[23]  J. Lindon,et al.  NMR of biofluids: detection of 2H-acetate and 2H-formate in urine as an indicator of microbiological contamination. , 1993, Journal of pharmaceutical and biomedical analysis.

[24]  H. Antoniades,et al.  Insulin and obesity in the Zucker genetically obese rat "fatty". , 1972, Endocrinology.

[25]  I. Messana,et al.  Proton nuclear magnetic resonance spectral profiles of urine in type II diabetic patients. , 1998, Clinical chemistry.

[26]  I. Wilson,et al.  A multi-analytical platform approach to the metabonomic analysis of plasma from normal and Zucker (fa/fa) obese rats. , 2006, Molecular bioSystems.

[27]  I. Wilson,et al.  A 1H NMR spectroscopic study of the biochemical effects of ifosfamide in the rat: evaluation of potential biomarkers , 2000 .

[28]  A R Tate,et al.  Investigation of the metabolite variation in control rat urine using (1)H NMR spectroscopy. , 2001, Analytical biochemistry.

[29]  E Holmes,et al.  Development of a model for classification of toxin‐induced lesions using 1H NMR spectroscopy of urine combined with pattern recognition , 1998, NMR in biomedicine.

[30]  Ian D Wilson,et al.  Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-TOFMS): detection of strain, diurnal and gender differences. , 2003, The Analyst.

[31]  Robert S Plumb,et al.  Metabonomics: the use of electrospray mass spectrometry coupled to reversed-phase liquid chromatography shows potential for the screening of rat urine in drug development. , 2002, Rapid communications in mass spectrometry : RCM.

[32]  E Holmes,et al.  Investigations into biochemical changes due to diurnal variation and estrus cycle in female rats using high-resolution (1)H NMR spectroscopy of urine and pattern recognition. , 2001, Analytical biochemistry.